During the corresponding time, Neurometrix Inc saw a revenue deteriorated by -36.86 % year on year, sequentially revenue fell by -60.9 %. While revenue at the Neurometrix Inc 's corporate clients
Neurometrix Inc's Comment on Sales, Marketing and Customers
The company serves customers who regularly order or subscribe to aftermarket products, focusing on active, installed user bases. Its products include Quell, a wearable device authorized by the FDA for symptomatic relief and management of lower extremity chronic pain and fibromyalgia symptoms. Quell consists of a device worn on the upper calf, an electrode, and smartphone and Apple Watch applications integrated with the Quell Health Cloud. Over 205,000 Quell devices have been shipped through 2024. The company also offers DPNCheck, a nerve conduction test device used by primary care physicians, endocrinologists, podiatrists, and other clinicians at the point of care to detect and monitor peripheral neuropathies. DPNCheck includes a hand-held device, a single patient-use biosensor, and PC-based software for data management and electronic medical record integration. More than 9,300 DPNCheck devices have been shipped through 2024, with over 4 million patient studies performed using related NC-stat technology. The company targets medical professionals and patients managing chronic pain and peripheral neuropathies.
NeuroMetrix, a pioneering health-care firm focusing on developing and marketing cutting-edge wearable medical technology, today announced significant strides taken to increase shareholder value. This recent came into action following valuable feedback and advice from one of its most significant shareholders. The aim was to create and establish better and stronger financial positioning, which would manifest into more substantial and considerable value to the shareholders. Taking swift and decisive action in response to the feedback, NeuroMetrix has indeed proven its commitment to delivering value to its shareholders. A board that addresses and responds to its shareholders concerns, especially those who have...
presents remarkable findings from a recent publication by NeuroMetrix, Inc., announcing the successful detection of diabetic peripheral neuropathy (DPN) using DPNCheck technology. The study highlights the effectiveness of DPNCheck as a standalone method or in combination with standard electrocardiography (EKG) for accurately diagnosing DPN.Study Overview:In a groundbreaking study conducted by NeuroMetrix, DPNCheck demonstrated its ability to precisely diagnose DPN. Diabetic Peripheral Neuropathy affects millions worldwide, leading to a range of debilitating symptoms and increased healthcare burden. The study aimed to determine whether DPNCheck, either independently or complemented with EKG, offered a reliab...
NeuroMetrix, a pioneer in neurotechnology, is pleased to announce the publication of results from a Phase 2 clinical trial of Quell in the prestigious Journal of Pain. This groundbreaking study, funded by the National Institutes of Health (NIH), demonstrates that Quell effectively improves the painful symptoms associated with Chemotherapy Induced Peripheral Neuropathy (CIPN). The findings of this peer-reviewed publication bring hope to millions of cancer patients undergoing chemotherapy. Chemotherapy is a cornerstone of modern cancer treatment, but its debilitating side effects often outweigh its benefits. CIPN, a common adverse effect of chemotherapy, affects approximately 30-40% of patients, causi...
Neurometrix Inc’s Comment on Sales, Marketing and Customers
The company serves customers who regularly order or subscribe to aftermarket products, focusing on active, installed user bases. Its products include Quell, a wearable device authorized by the FDA for symptomatic relief and management of lower extremity chronic pain and fibromyalgia symptoms. Quell consists of a device worn on the upper calf, an electrode, and smartphone and Apple Watch applications integrated with the Quell Health Cloud. Over 205,000 Quell devices have been shipped through 2024. The company also offers DPNCheck, a nerve conduction test device used by primary care physicians, endocrinologists, podiatrists, and other clinicians at the point of care to detect and monitor peripheral neuropathies. DPNCheck includes a hand-held device, a single patient-use biosensor, and PC-based software for data management and electronic medical record integration. More than 9,300 DPNCheck devices have been shipped through 2024, with over 4 million patient studies performed using related NC-stat technology. The company targets medical professionals and patients managing chronic pain and peripheral neuropathies.
Sources:
Neurometrix Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Neurometrix Inc’s corporate clients.
For your research, we’ve provided 9 tables on Neurometrix Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
